MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    LRRK2-Associated Parkinsonism With and Without In Vivo Evidence of Pathologic Alpha-Synuclein: Clinical and Biomarker Characterization

    L. Chahine, D. Lafontant, C. Choi, H. Iwaki, M. Brumm, R. Alcalay, K. Nudelman, A. Dagher, K. Merchant, A. Vo, Q. Tao, C. Venuto, K. Kieburtz, K. Poston, S. Bressman, P. Gonzalez Latapi, B. Avants, C. Coffey, D. Jennings, E. Tolosa, A. Siderowf, K. Marek, T. Simuni (Pittsburgh, USA)

    Objective: To compare clinical and biomarker features and rate of progression among LRRK2-associated parkinsonism cases with and without in vivo evidence of pathologic alpha-synuclein (asyn)…
  • 2024 International Congress

    Functionality Analysis of Immunoregulatory Cells Stimulated with Dopaminergic Agonists in People Living with Parkinson’s Disease

    AY. Regalado-Mustafá, DD. álvarez-Luquín, A. Guevara-Salinas, MA. Bravo-Martinez, EJ. Gallegos-Altamirano, CF. álvarez-Hernández, E. Ichikawa-Escamilla, AM. Peralta-Maza, V. Morales-Ruiz, EE. Sevilla-Reyes, JI. Velasco-Velázquez, JE. Estudillo-Hernández, M. Rodríguez-Violante, LV. Adalid-Peralta (Mexico City, Mexico)

    Objective: To evaluate the effect of dopaminergic agonists (DA) on the activation and functionality of regulatory cells in People living with Parkinson's Disease (PwP). Background:…
  • 2024 International Congress

    Early GBA-Related Parkinson’s Disease has a Distinct Clinical Phenotype and Cholinergic Innervation

    S. Slingerland, S. Zee, G. Carli, A. Slomp, E. D'Angremont, J. Boertien, T. Laar (Groningen, Netherlands)

    Objective: This study aims to characterize the clinical features and cholinergic innervation of early Parkinson’s disease (PD) patients with GBA mutations (GBA-PD). Background: The GBA-PD…
  • 2024 International Congress

    Synaptic Density Loss in Parkinson’s Disease Independent of Age: Preliminary Findings using [18F]SynVesT-1 PET Tracer

    S. Martin, C. Uribe, K. Desmond, N. Vasdev, A. Strafella (Toronto, Canada)

    Objective: To determine whether synaptic density differs in the brain of people with Parkinson’s disease and healthy controls using the [18F]-SynVesT-1 PET tracer. Background: The…
  • 2024 International Congress

    From Images to Insights: Subtyping Parkinson’s Disease Using Unsupervised Learning on MRI Data

    D. Teixeira-Dos-Santos, A. De-Oliveira-Franco, A. Bieger, C. Mattjie, F. Suzuki, G. Magalhães Pereira, J. Rossi Catao, L. Angi Souza, L. Silveira Kupssinskü, L. Vinícius Moura, MA. Machado Schlindwein, R. Ravazio, S. Duarte Pinto, T. Hugentobler Schlickmann, E. R. Zimmer, MA. de Bastiani, R. C. Barros, AF. Schumacher Schuh (Porto Alegre, Brazil)

    Objective: To explore the heterogeneity of Parkinson's disease (PD) using unsupervised clustering of neuroimaging data, aiming to identify distinct subtypes based on volumetric features. Background:…
  • 2023 International Congress

    Effects of Eromomastax speciosa in a Gastric Ulcer in a 6-hydroxydopamine (6-OHDA)-induced Rat Model of Parkinson’s Disease.

    GL. Ndji Otto, P. Amang, H. Adjia (Bertoua, Cameroon)

    Objective: To investigate the extract of Eromomastax speciosa neuroprotective/gastroprotective potential in the indomethacin (IND)-induced gastric ulcer in a 6-hydroxydopamine (6-OHDA)-induced PD model. Background: Parkinson's disease…
  • 2023 International Congress

    Arm swing deviations in patients with PD at different gait velocities

    S. Mainka, G. Ebersbach (Beelitz-Heilstaetten, Germany)

    Objective: To assess bilateral arm swing (AS) and other gait parameters in patients with PD and healthy subjects (HS) at various gait speeds and to…
  • 2023 International Congress

    Identification of reproducible metabolites for Parkinson’s Disease diagnosis using clinical data and computational modelling

    X. Luo, YJ. Liu, A. Balck, C. Klein, R. Fleming (Galway, Ireland)

    Objective: To identify replicated metabolic markers of Parkinson’s Disease (PD) diagnosis from metabolomic studies and predict additional metabolic markers using computational metabolic modelling. Background: Reported metabolic markers of…
  • 2023 International Congress

    Country and Sex Differences in Diagnosis Latency of Parkinson’s Disease in Latin American Populations

    J. Ramchandra, M. Inca-Martinez, TP. Leal, E. Gatto, F. Micheli, BL. Santos-Lobato, F. Cardoso, G. Letro, P. Braga-Neto, V. Peixoto, AF. Schumacher-Schuh, C. Rieder, V. Tumas, V. Borges, P. Chana, P. Saffie, P. Olguin, A. Colombo, JL. Orozco Vélez, C. Velez-Pardo, M. Del Rio, A. Medina, M. Rodriguez-Violante, AJ. Hernandez-Medrano, D. Martinez-Ramirez, A. Ruiz-Contreras, A. Lazaro-Figueroa, P. Reyes, M. Cornejo-Olivas, AC. Medina Colque, JE. Rios Pinto, A. Viñuela, IF. Mata (Cleveland, USA)

    Objective: To compare the latency in Parkinson’s Disease (PD) diagnosis, from onset of motor symptoms to clinical diagnosis, by sex in Latin America. Background: In…
  • 2023 International Congress

    Accelerometric Classification of Resting and Postural Tremor in Essential Tremor and Parkinson’s Disease

    C. Hennen, T. Berger, GA. Brandt, JN. Strelow, H. Jergas, JC. Baldermann, MT. Barbe, JN. Petry-Schmelzer, TA. Dembek (Cologne, Germany)

    Objective: To investigate the predictive value of different accelerometry metrics for clinical ratings of Essential Tremor (ET) and tremor in Parkinson’s Disease (PD). Background: To…
  • « Previous Page
  • 1
  • …
  • 92
  • 93
  • 94
  • 95
  • 96
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley